Cellular mechanisms of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma

Tumori

Volumn 94, Issue 4, 2008, Pages 523-530

  Kyung, Hee Lee ^a   Eun, Young Choi ^a   Myung, Soo Hyun ^a   Jong, Ryul Eun ^a   Byung, Ik Jang ^a   Tae, Nyeun Kim ^a   Heon, Ju Lee ^a   Dong, Shik Lee ^a   Sung, Su Yun ^a   Hong, Jin Kim ^a   Jung, Hye Kim ^a   Kim, Jae Ryong ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

Hepatocyte growth factor; Metastasis; Mitogen activated protein kinase; Urokinase plasminogen activator

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UROKINASE;

ARTICLE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 54749156297     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400414     Document Type: Article

References (23)

1. Junbo H, Li Q, Zaide W, Yunde H: Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis. In Vivo, 13: 177-180, 1995.
2. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R: Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev, 13: 41-59, 2002.
3. Longati P, Comoglio PM, Bardelli A: Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. Curr Drug Targets, 2: 41-55, 2001.
4. Miyake H, Hara L, Yamanaka K, Arakawa S, Kamidono S: Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol, 14: 35-41, 1999.
5. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ: Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer, 61: 597-600, 1995.
6. Lee KH, Hyun MS, Kim JY: Invasion-metastasis by hepatocyte growth factor/c-Met signaling concomitant with induction of urokinase plasminogen activator in human pancreatic cancer: role as therapeutic target. Cancer Res Treat, 35: 207-212, 2003.
7. Xing RH, Rabbani SA: Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int J Cancer, 67: 423-429, 1996.
8. English J, Pearson G, Wilsbacher J, Swantek J, Karandikar M, Xu S, Cobb MH: New insights into the control of MAP kinase pathways. Exp Cell Res, 253: 255-270, 1999.
9. Iwasaki S, Iguchi M, Watanabe K, Hoshino R, Tsujimoto M, Kohno M: Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2. J Biol Chem, 274: 26503-26510, 1999.
10. Schmidt CM: The role of Gi, Gs and Gq/11-protein linked MAPK signaling in the regulation of hepatocellular carcinoma growth. UMI Publishers, Washington, DC, 1998 (Dissertation).
11. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun, 236: 54-58, 1997.
12. Restuccia C, Angelucci A, Gravina GL, Villanova I, Teti A, Albini A, Bologna M: Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer, 85: 407-415, 2000.
13. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E: Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology, 25: 619-623, 1997.
14. Payne DM, Rossomando AJ, Martino P, Erickson AK, Her JH, Shabanowitz J, Hunt DF, Weber MJ, Sturgill TW: Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J, 10: 885-892, 1991.
15. Garrington TP, Johnson GL: Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol, 11: 211-218. 1999.
16. Delehedde M, Sergeant N, Lyon M, Rudland PS, Fernig DG: Hepatocyte growth factor/ scatter factor stimulates migration of rat mammary fibroblasts through both mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt pathways. Eur J Biochem, 269: 4423-4429, 2001.
17. Koochekpour S, Sartor O, Hiraiwa M, Lee TJ, Rayford W, Remmel N, Sandhoff K, Minokadeh A, Patten DY: Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells. Asian J Androl, 7: 147-158, 2005.
18. Matsumoto K, Nakamura T, Kramer RH: Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J Biol Chem, 69: 31807-31813, 1994.
19. Lai JF, Kao SC, Jiang ST, Tang MJ, Chan PC ,Chen HC: Involvement of focal adhesion kinase in hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells. J Biol Chem, 275: 7474-7480, 2000.
20. Lee KH, Choi EY, Kim MK, Hyun MS, Jang BI, Kim TN, Kim SW, Song SK, Kim JH. Kim JR: Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines. Exp Molec Med, 38: 27-35, 2006.
21. SAPK1. Cancer Res, 63: 1684-1695, 2003.
22. Xian ZD, Thomas EA: MEK/ERK-mediated proliferation is negatively regulated by P38 MAP kinase in the hman pancreatic cancer cell line, PANC-1. Biochem Biophy Res Commun, 282: 447-453, 2001.
23. Lee KH, Hyun MS, Kim JY: Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis. Clin Exp Meta, 20: 499-505, 2003.